PH
PHCUF.US Photocure ASA
- Market cap
- USD 152M
- P/E
- 29.7x
- P/B
- 2.50x
- ROE
- 12.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PHCUF.US undervalued?
Graham numberPHCUF.US trades 81.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Photocure ASA fundamental analysis
No fundamental analysis for Photocure ASA yet.
Photocure ASA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Photocure ASA
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through two segments, Commercial Franchise and Development Portfolio. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It is also developing Cevira, a photodynamic drug-device combination product candidate for the non-surgical treatment of high-grade cervical dysplasia. …
Full company profilePhotocure ASA financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Photocure ASA annual financial statements (NOK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 144M | 151M | 182M | 282M | 256M | 361M | 393M | 501M | 525M | 532M | 729M |
| Gross Profit | 134M | 139M | 164M | 259M | 238M | 336M | 370M | 475M | 495M | 490M | 679M |
| Operating Income | -15.9M | -45.2M | -37.9M | 42.7M | -13.3M | 9.39M | -49.0M | 27.8M | 20.4M | 110M | 207M |
| EBITDA | -8.01M | -33.1M | -10.5M | 59.0M | -6.91M | 16.8M | -21.0M | 63.8M | 74.1M | 139M | 249M |
| Net Income | 35.3M | -34.7M | -36.7M | 31.8M | -22.4M | -30.9M | -71.9M | 979K | -4.81M | -1.52M | 75.3M |
| EPS | 1.64 | -1.61 | -1.70 | 1.46 | -0.91 | -1.15 | -2.66 | 0.04 | -0.18 | -0.06 | 2.79 |
| Balance Sheet | |||||||||||
| Total Assets | 286M | 263M | 231M | 257M | 776M | 790M | 719M | 712M | 739M | 707M | 879M |
| Total Liabilities | 33.9M | 45.0M | 54.9M | 48.8M | 268M | 287M | 256M | 229M | 237M | 223M | 296M |
| Shareholders' Equity | 252M | 218M | 176M | 209M | 508M | 503M | 463M | 483M | 500M | 484M | 583M |
| Cash & Short-term Investments | 165M | 125M | 103M | 121M | 330M | 319M | 265M | 256M | 289M | 239M | 162M |
| Total Debt | - | - | - | 6.95M | 53.9M | 78.7M | 54.4M | 33.6M | 16.8M | 120M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 19.2M | -23.6M | -24.1M | 20.7M | 15.6M | 23.9M | -2.02M | 48.3M | 76.8M | 43.9M | 111M |
| Capital Expenditure | 22.1M | 18.6M | 2.19M | 1.24M | 1.61M | 3.70M | 3.61M | 12.3M | 11.4M | 21.7M | 27.5M |
| Free Cash Flow | -2.91M | -42.2M | -26.3M | 19.4M | 14.0M | 20.2M | -5.63M | 36.0M | 65.3M | 9.98M | 83.2M |
| Ratios | |||||||||||
| ROE | 14.0% | -15.9% | -20.8% | 15.3% | -4.4% | -6.1% | -15.5% | 0.2% | -1.0% | -0.3% | 12.9% |
| ROA | 12.4% | -13.2% | -15.9% | 12.4% | -2.9% | -3.9% | -10.0% | 0.1% | -0.7% | -0.2% | 8.6% |
| Net Profit Margin | 24.6% | -23.0% | -20.2% | 11.3% | -8.7% | -8.6% | -18.3% | 0.2% | -0.9% | -0.3% | 10.3% |
| Debt to Equity | - | - | - | 0.03x | 0.11x | 0.16x | 0.12x | 0.07x | 0.03x | 0.25x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Photocure ASA dividends
Photocure ASA has not paid dividends in the last 9 fiscal years.
Who owns Photocure ASA
- Insiders 2.39%
- Institutions 38.08%
- Public & others 59.53%
- Shares outstanding 27.0M
- Free float 19.7M
Photocure ASA company profile
- Company name
- Photocure ASA
- Ticker
- PHCUF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 99
- Fiscal year end
- December
- Address
- Hoffsveien 4, Oslo, Norway, 0275
- Phone
- 47 22 06 22 10
- Website
- photocure.com
About Photocure ASA
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through two segments, Commercial Franchise and Development Portfolio. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It is also developing Cevira, a photodynamic drug-device combination product candidate for the non-surgical treatment of high-grade cervical dysplasia. The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira; and a strategic agreement with Richard Wolf GmbH to develop and commercialize a 4K LED high-definition reusable blue light cystoscope based on Richard Wolf's System blue technology. It sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. It has partnership with Artera for digital pathology AI test evaluation for bladder cancer. The company operates in the Nordic countries, Germany, France, Austria, the United Kingdom, the Benelux, Italy, other European countries, Canada, and the United States. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.
Photocure ASA management
9- Mr. Daniel SchneiderPresident & CEO
- Anja Gossens-von der HeidtHead of Global Human Resources
- Dr. Anders Neijber M.D.Chief Medical Officer of Global Medical Affairs, Clinical Development and R&D
- Jane HealyVice President & General Manager of Europe
- Mr. Dennis CamporealeChief Financial Officer
- Mr. Priyam Shah????Vice President of Investor Relations
- Mr. Christopher D. ThibodeauChief Operating Officer Biomarker · born 1971
- Mr. Tolv HillestadGroup Controller
- Mr. Dick PetersVice President of Finance & IT